Clinical Trial Detail

NCT ID NCT02724878
Title Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Dana-Farber Cancer Institute
Indications

renal cell carcinoma

Therapies

Atezolizumab + Bevacizumab + Capecitabine

Age Groups: adult

No variant requirements are available.